Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 6Completed 5Withdrawn 3Terminated 3Recruiting 3Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Breast Neoplasms 3Prostatic Neoplasms 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1MMR-D/MSI-H Colorectal Cancers 1Lymphoma 1Leiomyosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × niraparib × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04762901 2022-04-26

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Wake Forest University Health Sciences

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT04655183 2021-06-30

Study of M4344 in Combination With Niraparib

EMD Serono

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡